How to access Doptelet from Dubai, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient with chronic immune thrombocytopenia (ITP) that has had insufficient response to a prior therapy, or a patient with chronic liver disease (CLD)-associated thrombocytopenia scheduled for a procedure, may receive a prescription for Doptelet (avatrombopag) from their treating haematologist or hepatologist. Doptelet is FDA-approved in the United States and developed by Sobi (acquired from Dova Pharmaceuticals). It is an oral thrombopoietin (TPO) receptor agonist taken with food. Where Doptelet is not on an Emirati hospital formulary, a named-patient import pathway via UAE Ministry of Health and Prevention (MoHAP) is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Doptelet is an oral tablet taken once daily (with food) for chronic ITP, or on a defined pre-procedural schedule for CLD-associated thrombocytopenia (once daily for 5 days with the procedure scheduled on day 10-13). Dosing in ITP is titrated to platelet response. Your treating physician confirms diagnosis, baseline platelet counts, prior therapy history, thromboembolic risk assessment, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Doptelet legally importable into Dubai?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient / special-import framework. The pathway allows an Dubai-licensed (under DHA) physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating physician. Diagnosis, platelet history, prior therapy history, and clinical rationale.
- Pre-treatment workup. Baseline CBC, thromboembolic risk assessment per labeling.
- MoHAP named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Doptelet is an oral tablet with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming chronic ITP or CLD-associated thrombocytopenia, platelet counts, prior therapies, and Doptelet as the indicated treatment
- Verification of their Emirati medical registration
- Patient identifier
- Baseline workup confirmation
- Planned dosing regimen and monitoring cadence
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for TPO receptor agonists.
Costs and timing
Doptelet's US cash-pay drug-only reference price for a 30-day ITP supply sits in a broad indicative range of roughly USD 9,000-13,000 depending on dose; the pre-procedural CLD course (5 tablets) is priced as a short course. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete application is submitted. Refills (for chronic ITP) ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Mechanism, approval status, and treatment course
Doptelet (avatrombopag) is a oral, small-molecule thrombopoietin receptor agonist (TPO-RA) that binds the transmembrane domain of the c-Mpl receptor at a site distinct from endogenous TPO and stimulates megakaryocyte proliferation and platelet production. FDA approval: 2018. EMA approval: 2019. The labelled indication is the thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, and thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Doptelet is supplied through the US specialty distribution channel only; Reserve Meds sources from a US-licensed authorised wholesaler under Drug Supply Chain Security Act (DSCSA) chain-of-custody and ships under the documentation framework DHA reviewers expect.
Dosing. Chronic liver disease pre-procedure: 60 mg once daily for 5 days starting 10 to 13 days before the procedure (baseline platelets 40 to less than 50 x 10^9/L), or 40 mg once daily for 5 days (baseline platelets less than 40 x 10^9/L). ITP: 20 mg once daily, titrated to a target platelet count of at least 50 x 10^9/L, maximum 40 mg once daily. Taken with food. The Dubai treating physician documents the planned dose, the titration interval, and the response endpoint in the DHA application package.
Tertiary referral landscape in Dubai
Doptelet cases in Dubai are most commonly initiated and followed at tertiary referral centres with subspecialty expertise in the indication. These include American Hospital Dubai, Mediclinic City Hospital, and Saudi German Hospital Dubai. The treating physician of record (the Dubai-licensed neurologist, haematologist, or relevant subspecialist) holds clinical responsibility for the case; Reserve Meds does not interpose between the patient and the prescriber. DHA pathway submissions are filed by the treating physician or the hospital pharmacy department, and Reserve Meds supplies the regulatory documentation package that DHA reviewers expect.
Where the patient is followed at a non-tertiary clinic, the patient is typically referred for the Doptelet initiation visit to one of the centres above and then returns to local follow-up with monthly or quarterly tertiary review, depending on the clinical picture. Reserve Meds coordinates the refill cadence so that the next shipment is in country at least 7 days before the patient's current supply ends.
Monitoring and continuity of care
The Dubai treating physician follows a standard monitoring schedule once Doptelet is initiated:
- Platelet count weekly during titration in ITP and at day 10 to 13 (procedure day) in the chronic-liver-disease indication
- Liver function tests (ALT, AST, total bilirubin) at baseline and at clinical intervals in chronic-liver-disease patients given the TPO-RA class-association with hepatobiliary signals (though avatrombopag specifically lacks the hepatotoxicity warning that applies to eltrombopag)
- Thrombosis screen in patients with portal-vein thrombosis history or other thrombophilic risk factors; TPO-RAs can theoretically promote portal-vein thrombosis in cirrhotic patients
Reserve Meds is not involved in the clinical monitoring itself, but supplies refill cadence reminders to the patient and the treating physician so that the next-month supply is delivered in advance of the patient's next scheduled clinic visit. The first refill is shipped at week 3 of the initial cycle so that any titration adjustment from the 4-week visit can be reflected in the dose supplied for cycle 2.
Concomitant medications and safety considerations
Before Doptelet is initiated, the Dubai treating physician reconciles every concomitant prescription, over-the-counter, and herbal medicine the patient is taking. Key safety points the physician documents in the DHA package:
- Thromboembolic events including portal-vein thrombosis have been reported, particularly in chronic-liver-disease patients with pre-existing thrombophilic factors; the haematologist or hepatologist screens for risk before initiation
- Rebound thrombocytopenia below baseline can occur within two weeks of discontinuation; platelet monitoring continues for at least 4 weeks after the final dose
- Avatrombopag has no documented food-interaction issues other than the requirement to take with food for adequate absorption; unlike eltrombopag it does not require a 4-hour separation from polyvalent cations such as calcium or iron supplements
The patient is given a written counselling document in the language of care identifying which symptoms warrant immediate clinical contact and which can wait for the next scheduled visit. Reserve Meds supplies a generic counselling-document template that the treating physician adapts to the patient's case.
Funding considerations in Dubai
Doptelet is supplied on a cash-pay basis. Some Dubai private medical insurers consider named-patient imports of FDA-labelled medicines on a case-by-case basis, particularly when the insurer's medical director can review the clinical rationale letter and the DHA authorisation. Reserve Meds supplies the documentation package the insurer requires for review but does not adjudicate or process claims directly.
For self-pay patients, Reserve Meds issues a transparent quote at intake covering the drug-only band, international logistics, DHA documentation handling, and concierge case coordination. The quote is fixed for the duration of the initial 90-day cycle and re-issued for each subsequent cycle if the dose changes. Patients are encouraged to ask their Dubai treating physician about manufacturer patient-assistance pathways where available, although most US manufacturer assistance programs are restricted to US residents.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Doptelet specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Tamper-evident, internationally tracked shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Dubai? Yes, when executed through the MoHAP named-patient framework with appropriate documentation.
How does Doptelet compare to other TPO agonists? Doptelet is taken with food (a notable practical difference from some other oral TPO agonists that have fasting requirements). Your physician will weigh practical and clinical factors.
Is the CLD pre-procedural course short? Yes, a typical pre-procedural course is 5 daily doses with the procedure scheduled a few days after completion, per labeling.
Will private insurance cover this? Cash-pay is the default. Some Emirati insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
How does Doptelet compare with eltrombopag and romiplostim? All three are TPO receptor agonists. Eltrombopag is oral but requires a 4-hour separation from polyvalent cations and carries a hepatotoxicity boxed warning. Romiplostim is a weekly subcutaneous injection. Avatrombopag is oral, taken with food, with no cation-separation requirement and no hepatotoxicity boxed warning. Selection depends on patient preference, comorbidities, and access.
Is Doptelet a curative therapy for ITP? No. Doptelet is a chronic platelet-supportive therapy. Approximately one third of ITP patients on TPO-RAs achieve sustained platelet response off treatment after a planned taper attempt; the remaining two thirds require ongoing therapy or transition to another agent.
Can Doptelet be used during pregnancy? Pregnancy data are limited. The FDA label advises that the potential benefit must outweigh the potential risk; an experienced haematologist co-manages with the obstetrician. Most clinicians prefer alternative ITP-in-pregnancy strategies (IVIG, corticosteroids) unless contraindicated.
What if the patient does not respond to Doptelet within 4 weeks? The dose is titrated up to the 40 mg/day maximum in ITP. If platelet response remains inadequate at the maximum dose by week 4, the haematologist reconsiders the underlying diagnosis (especially excluding bone-marrow disorders) and may switch to an alternative TPO-RA or non-TPO-RA therapy.
Next step
For Doptelet coordination in Dubai, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.